Tvardi Therapeutics increases ATM offering by up to $9.7M

Tvardi Therapeutics, Inc.

Filed prospectus supplement to increase ATM offering capacity by $9,689,765 in common stock.
Prior 12-month sales under existing program: 3,110,769 shares for ~$11.0M gross proceeds.
Offering subject to 'baby shelf' rule; non-affiliate market value $62.2M based on 12.4M shares at $5.00.
No additional shares will be sold under prior prospectus after supplement date.
Legal opinion from Cooley LLP filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.